We studied cefotaxime (CTX) and desacetylcefotaxime (dCTX) pharmacokinetics in 19 children (ages, 7 to 16 years) with various degrees of renal function. The patients were stratified into three groups according to 24-h urinary creatinine clearance (CLCR) values: group I, CLCR > 80 ml/min/1.73 m2 (n = 7); group II, CLCR from 30 to 80 ml/min/1.73 m2 (n = 6); and group III, CLCR < 30 ml/min/1.73 m2 (n = 6). A single 50-mg/kg dose of CTX was given intravenously to each patient after which blood and urine samples were collected and analyzed for CTX and dCTX by high-performance liquid chromatography. Safety was assessed by pre-and poststudy blood chemistries and urinalysis. The mean values for total body clearance of CTX for groups I, II, and III were 158.1 ± 38.8, 118.3 ± 50.8, and 84.8 ± 11.7 ml/min/1.73 M2, respectively (P < 0.01). Renal clearance also decreased across groups, I, II, and III, with values of 77.5 ± 20.2, 41.3 ± 18.5, and 11.4 ± 7.7 ml/min/1.73 m2 respectively (P < 0.0001). Both the CTX fraction nonrenally cleared and elimination half-life increased with decreasing renal function. The CTX volume of distribution at steady state was not affected by renal disease. The renal clearance values of dCTX were 146.4 ± 71.4, 64.5 ± 32.1, and 14.4 ± 8.7 ml/min/1.73